News | Stroke | August 15, 2022

Ochsner and Tulane Collaboration Uncovers What Happens to Genes Inside Artery Plaques to Trigger Strokes

Researchers at Ochsner Health and Tulane University School of Medicine have identified the genes that become active in carotid arteries when plaque rupture causes a stroke.

Getty Images


August 15, 2022 —  Researchers at Ochsner Health and Tulane University School of Medicine have identified the genes that become active in carotid arteries when plaque rupture causes a stroke. The work, published in Scientific Reports, was made possible by acquiring samples closer to the time of the stroke than previously possible. The results provide a picture of what the cells in the plaque are doing near the moment they induce a stroke. 

Cardiovascular disease is the leading cause of death globally, responsible for an estimated 17.9 million deaths annually and is often the result of plaques that build up in the arteries. When these plaques burst, they can release material into the bloodstream that blocks oxygen from reaching the heart or brain. There is no way to determine precisely when a plaque will rupture. 

Previous studies have relied on carotid artery samples obtained after the patient’s death or months after the stroke or heart attack. This either limits the information that can be obtained or misses events that occur only at the time of rupture. For the first time, the current study sequenced the RNAs in plaques from patients who had experienced a stroke within two to five days. In doing so, the team created a picture of the RNAs active closer to the time of rupture than previously possible. 

The investigators found that plaques that rupture have increased inflammation coupled with processes that would cause the loss of a portion of the plaque that protects against rupture, known as the fibrous cap. Surprisingly, the researchers found that ruptured plaques had increased B-cell markers, a white blood cell whose role in plaque rupture has not previously been appreciated. 

Carotid artery blockage is a common cause of some ischemic strokes, which happens when the blood supply to part of the brain is interrupted, preventing brain tissue from getting necessary oxygen and nutrients. Because the mechanisms that lead to some strokes and most heart attacks involve the same plaque rupture events, these findings also have implications for heart disease. 

“Inflammation is a known risk factor in atherosclerosis, leading to stroke and heart attacks,” said Hernan Bazan, MD, the John Ochsner Endowed Professor for Cardiovascular Innovation at Ochsner Health. “Carotid and coronary plaques develop a protective cap that, for unclear reasons, thins, making strokes and heart attacks more likely.” 

Study senior author Cooper Woods, PhD, Associate Professor of Physiology and Medicine at Tulane University School of Medicine, emphasizes, “Identifying the genes that promote this thinning gives us new targets for therapeutics and diagnostics to prevent heart attacks and strokes.” 

The National Institutes of Health and the Endowed John Ochsner Professorship in Cardiovascular Innovation support the research. Dr. Bazan was appointed as John Ochsner Chair in Cardiovascular Innovation last year, a position created following the death of nationally renowned cardiovascular surgeon Dr. John Ochsner to honor his legacy and impact the field of medicine. Dr. Bazan carries innovation in atherosclerotic mechanisms and acute carotid and stroke clinical research through the position. This support will continue through at least 2026. 

A Nature journal, Scientific Reports, is the 5th most-cited journal in the world, with more than 696,000 citations in 2021. The full study is online at https://www.nature.com/articles/s41598-022-17546-9

To learn more about the Endowed John Ochsner Professorship in Cardiovascular innovation: https://research.ochsner.org/research-announcements/2021/johvi 


Related Content

News | Cardiovascular Clinical Studies

April 24, 2024 —Hello Heart, a digital leader in preventive heart health, today announced results from its latest study ...

Home April 24, 2024
Home
News | Cardiovascular Clinical Studies

April 22, 2024 — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, welcomes the ...

Home April 22, 2024
Home
News | Cardiovascular Clinical Studies

April 16, 2024 — CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Administering tranexamic acid (TxA), a drug used to reduce bleeding during heart surgery, topically ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Using a web application to qualify individuals for treatment with a nonprescription statin closely ...

Home April 09, 2024
Home
Subscribe Now